Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omacetaxine and Venetoclax in R/R AML or MDS with RUNX1 Mutation
NCT04874194Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Dec 2021
- Primary completion
- Sep 2024
- Modality
- Nucleic Acid-Directed Small Molecules, Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of homoharringtonine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (6 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Recommended Phase 2 Dose up to 30 days and Complete Remission. Started Dec 2021; status: terminated.
02
Drugs
homoharringtonine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT04874194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04874194.